AAO 2023: New Positive Data for Exudative Age-Related Macular Degeneration

Vaidehi S. Dedania, MD

November 10, 2023

Vaidehi S. Dedania, MD, presents an overview of phase 3 data regarding the treatment of exudative age-related macular degeneration, as presented at AAO 2023.

Dr Dedania begins with a glimpse at the TENAYA and LUCERNE studies, noting how both in post hoc analyses demonstrated greater efficacy of the monoclonal antibody faricimab compared with aflibercept. The GALE and GATHER2 trials offered similar positive results, indicating extended treatment effects and reduced geographic atrophy. Dr Dedania concludes with speculation about emerging therapeutic trends such as TIE pathway inhibition, gene therapy, and continued research into tyrosine kinase inhibitors.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: AAO 2023: New Positive Data for Exudative Age-Related Macular Degeneration - Medscape - Nov 10, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

AAO 2023: New Positive Data for Exudative Age-Related Macular Degeneration

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Vaidehi S. Dedania, MD

Comments

Email This

Feedback